Novo Nordisk has its sights set on Mexico. The Danish drugmaker has put that country next on its list to debut liraglutide in its new guise as a weight-loss drug.
The Persian Gulf is the newest emerging market for Big Pharma, the Wall Street Journal reports. Drugmakers have jumped on that opportunity, as evidenced by the number of new plants and distribution facilities they are putting there.
Are the BRIC countries passé in Big Pharma? Not exactly. But multinational pharma's newest trend lies in the Persian Gulf, the Wall Street Journal reports.
Two of the biggest players in Brazil's medical diagnostics industry are likely to confront major changes in the coming months-- both worth noting as global competitors seek to enter one of the largest emerging markets around.
Roche's new extended partnership with Cancer Genetics will expand molecular diagnostic cancer testing in the Caribbean and Central America as part of a three-year deal.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.
Big Pharma wants the U.S. to pull a big-gorilla act in India. With patents revoked and cheap generics foisted on them ahead of schedule--and more early copycats possibly on their way--multinational drugmakers are lobbying for an intervention.
Australian CRO Novotech is heading west with its global expansion effort, opening up shop in South Africa to broaden its access to diverse patient populations.